Ursula Brooks-Clemons
Psychiatric/Mental Health · Natchez, MSNPI 1558727560
Payments from drug & device makers
Across 139 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$579
- Axsome Therapeutics, Inc.$320
- Indivior Inc.$233
- Otsuka America Pharmaceutical, Inc.$217
- Alkermes, Inc.$214
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$206
- plus $816 from 10 others
What the payments were for
- Food & beverage$2,578100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $579 |
| Axsome Therapeutics, Inc. | 10 | $320 |
| Indivior Inc. | 12 | $233 |
| Otsuka America Pharmaceutical, Inc. | 12 | $217 |
| Alkermes, Inc. | 13 | $214 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $206 |
| Lundbeck LLC | 9 | $156 |
| Johnson & Johnson | 8 | $150 |
| Sunovion Pharmaceuticals Inc. | 8 | $141 |
| Vanda Pharmaceuticals Inc. | 5 | $102 |
| Corium, LLC | 4 | $88 |
| Avanir Pharmaceuticals, Inc. | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Pfizer | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
How this compares
$2,584 in reported general payments places this provider in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 17 | $52,918 |
| Abilify MaintenaAripiprazole | 18 | $49,755 |
| RexultiBrexpiprazole | 33 | $48,424 |
| VraylarCariprazine Hcl | 15 | $22,819 |
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $9,036 |
| TrintellixVortioxetine Hydrobromide | 17 | $8,110 |
| Bupropion XlBupropion Hcl | 30 | $2,678 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,735 |
| Quetiapine Fumarate | 93 | $1,476 |
| Clozapine | 15 | $1,350 |
| Olanzapine | 50 | $1,321 |
| Alprazolam | 151 | $1,125 |
| Divalproex Sodium | 30 | $885 |
| Trazodone Hcl | 107 | $684 |
| Oxcarbazepine | 23 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $217 | $98,18051 claims |
| Johnson & JohnsonInvega Sustenna | $150 | $52,91817 claims |
| AbbVieVraylar, Namzaric | $579 | $31,85532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Natchez
- Christa JonesNatchez$10K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Alanna WrightJackson$58K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
- Belinda EdwardsJackson$29K
- Lawanda GlassCleveland$22K
- Rebecca HartzogHattiesburg$17K
- Leigh CalcoteHattiesburg$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.